Legend Capital-Backed Harbour BioMed Acquires US Biotech Firm Harbour Antibodies

Shanghai-based biotechnology company Harbour BioMed, backed by Chinese investment firms Advantech Capital and Legend Capital, has acquired Netherlands-headquartered firm Harbour Antibodies BV to create a global oncology-focused biotechnology company.

Harbour BioMed used a combination of cash and equity to acquire the Cambridge, Massachusetts-based firm, says an announcement. No financial details were announced.

The acquisition was financed by Harbour BioMed's investors, Advantech Capital and Legend Capital, two China-focused investors with a particular emphasis on life sciences.

Harbour Antibodies' existing shareholders, ...

This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network

You May Also Like